Chapters Index (French) French Version Welcome page Contact

Other chemotherapies are, in fact, more or less experimental and should be administered in the strict respect of laws for protecting patients (in France, the Huriet Law):

• drafting of a protocol justifying the research,

• advice of an ethics committee,

• informed written consent from the patient,

• careful collection of all necessary data in order to report the progress or absence of progress.

This category of chemotherapies includes:

• lintracavity chemotherapy,

• intraarterial chemotherapy,

• intensive chemotherapy with autologous bone marrow transplantation (with the exception of a few pathologies for which this treatment has been clearly assessed),

• many associations of radiochemotherapy, yet to be assessed,

• any new treatment which is still in phase II or phase III trial stage before the publication of unequivocal results (and not a rapid, premature and unsatisfactory presentation).

Of course, treatment modalities for which the experimental results in well conducted studies are negative should not be prescribed even in 'experimental' situations or ”to continue to try do something for this poor patient”.